Keros Therapeutics Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on […]
Snail Games’ ARKade Ambassador Program Reshapes Gaming Connections
CULVER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail” or “the Company”), a leading, global […]
QCR Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results
MOLINE, Ill., Jan. 03, 2024 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (NASDAQ: QCRH) announced today that its fourth quarter and fiscal […]
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage […]
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for […]
Monthly information related to total number of voting rights and shares composing the share capital – December 31, 2023
Monthly information related to total number of voting rights and shares composing the share capital _ December 31, 2023 Article […]
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-Dr. Praveen Tipirneni, returns in full capacity as Chief Executive Officer from medical leave- WALTHAM, Mass., Jan. 03, 2024 (GLOBE […]
Gevo Announces Appointment of Katie Ellet to Board of Directors
ENGLEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Katie Ellet has […]
Oaktree Specialty Lending Corporation Schedules First Fiscal Quarter Earnings Conference Call for February 1, 2024
11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time LOS ANGELES, CA, Jan. 03, 2024 (GLOBE NEWSWIRE) — Oaktree Specialty […]
Foghorn Therapeutics Announces CFO Departure
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new […]
